279
Participants
Start Date
June 30, 2014
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2015
Dotarem®
Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Gadovist®/Gadavist®
Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Centro Neurologico ABC, México
Hospital CIMA, Chihuahua City
Morales Vargas Centro de Investigación S.C., León
Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey
University of Alabama at Birmingham, Birmingham
Cedars-Sinai Medical Center, Los Angeles
Yale University School Of Medicine, New Haven
University of Michigan Health System, Ann Arbor
Quest Research Institute, Farmington Hills
Spectrum Health, Grand Rapids
Washington University, St Louis
Temple University Hospital, Philadelphia
MUSC (Medical University of South Carolina), Charleston
UVM MRI Center for Biomedical Imaging, Burlington
University of Washington Medical Center, Seattle
Fundacion Abood Shaio, Bogotá
Fundacion Cardioinfantil Instituto de Cardiologia, Bogotá
Instituto Nacional de Cancerologia, Bogotá
Fundacion Instituto de Alta Tecnologia Medica de Antioquia IATM, Medellín
Hospital Pablo Tobon Uribe, Medellín
Centro Medico Imbanaco, Santiago de Cali
Winsett Rethman S.A. de C.V., Monterrey
Centro Regiomontano de Investigacion S.C., Monterrey
Clinical Research Institute S.C., Tlanepantla
Ajou University Hospital, Suwon
University of Arizona Medical Center, Tucson
Infinity Clinical Research, LLC, Hollywood
Winthrop University Hospital Clinical Trials Center, Mineola
Chonbuk national Univ Hosp, Jeonju
Chungbuk National University, Cheongju-si
Seoul St.Mary Hospital, Seoul
Asan medical center, Seoul
Lead Sponsor
Guerbet
INDUSTRY